FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3172808526> ?p ?o ?g. }

• W3172808526 endingPage "e19019" @default.
• W3172808526 startingPage "e19019" @default.
• W3172808526 abstract "e19019 Background: The outcomes in patients (pts) with newly diagnosed FLT3 mutated AML who are ineligible for intensive induction chemotherapy are poor. Added to a low intensity chemotherapy backbone, FLT3 inhibitors, such as midostaurin, sorafenib, and quizartinib, result in median OS of 8-17 months in the frontline (Gallogly ASH 2017, Ohanian AJH 2018, Swaminathan ASH 2017), and 4-8 months in relapsed/refractory (R/R) settings (Yilmaz JHO 2020, Ravandi Blood 2013). Quizartinib, a potent second generation FLT3 inhibitor demonstrated synergy with venetoclax (VEN) (a BCL-2 inhibitor) in AML cell lines and PDX models (Mali Haematologica 2020). We designed this study to evaluate the safety and efficacy of quizartinib, venetoclax, and decitabine combination in pts with R/R or newly diagnosed FLT3 mutated AML. Methods: Frontline cohort included pts who are ineligible for intensive induction chemotherapy, and R/R cohort included pts who received 5 or less prior treatments. All patients had a performance status of ECOG ≤2, adequate organ functions, and QTcF <450 msec prior to therapy. All pts underwent day 14 bone marrow, and venetoclax (400 mg/day) was put on hold in patients with bone marrow blasts ≤ 5% (or marrow aplasia). Those with day14 bone marrow blast >5% continued venetoclax for 21 days during cycle 1. All pts induced with 10 days of decitabine (20 mg/m2). In subsequent cycles, decitabine administered for 5 days. Quizartinib (30 or 40 mg/day) was administered daily continuously. Results: 21 pts were enrolled and 17 pts evaluable at the time of this report (4 are still within cycle 1). Of 13 pts with R/R AML (median 3 [range 1-5] prior therapies, 85% with ≥1 prior FLT3 inhibitor), 9 (69%) achieved CRc (2 CR, 7 CRi) with 4/9 and 5/9 responders FLT3-PCR and multicolor flow cytometry (MFC) negative, respectively. Thirty and 60-day mortality rates were 0% and 8%. Of 4 patients with newly diagnosed AML (median age 72), all achieved CRc (2 CR, 2 CRi) with 4/4 and 2/3 responders FLT3-PCR and MFC negative, respectively. 60-day mortality was 0% in the frontline cohort. No pts developed a dose limiting toxicity (DLT) with 30 mg/day quizartinib, however with the 40mg/day quizartinib 2 pts developed hematologic DLT (grade ≥3 neutropenia with a <5% cellular bone marrow lasting ≥42 days). Hence, quizartinib 30 mg/day dose was determined as recommended phase 2 dose for the triplet. Grade 3/5 non-hematologic toxicities in >2 pts included lung infections (N=9) and neutropenic fever (N=6). No QTcF prolongations >450 msec were noted. With a median follow-up of 7.2 months, the median OS was not reached in frontline cohort and was 7.1 months in R/R cohort. 2/4 and 5/9 responders underwent ASCT in frontline and R/R cohorts, respectively. All frontline pts were alive at the last follow-up; 3 were in CR and 1 relapsed disease. Of 9 responders in R/R cohort, 4 were alive (3 CR, 1 relapse) and 5 died (4 relapse, 1 CR). Conclusions: Decitabine + venetoclax + quizartinib is highly active in R/R FLT3-ITD mutated AML pts, with CRc rates of 69% and the median OS of 7.1 months. Accrual to the triplet continues and updated clinical and correlative data will be presented. Clinical trial information: NCT03661307." @default.
• W3172808526 created "2021-06-22" @default.
• W3172808526 creator A5000750846 @default.
• W3172808526 creator A5009316700 @default.
• W3172808526 creator A5009423275 @default.
• W3172808526 creator A5010786159 @default.
• W3172808526 creator A5020340537 @default.
• W3172808526 creator A5020626623 @default.
• W3172808526 creator A5022647201 @default.
• W3172808526 creator A5028081179 @default.
• W3172808526 creator A5050041791 @default.
• W3172808526 creator A5055045706 @default.
• W3172808526 creator A5060758278 @default.
• W3172808526 creator A5061026876 @default.
• W3172808526 creator A5070065917 @default.
• W3172808526 creator A5079262854 @default.
• W3172808526 creator A5088280758 @default.
• W3172808526 creator A5088307376 @default.
• W3172808526 creator A5090435894 @default.
• W3172808526 creator A5091492845 @default.
• W3172808526 date "2021-05-20" @default.
• W3172808526 modified "2023-10-17" @default.
• W3172808526 title "Quizartinib with decitabine and venetoclax (triplet) is highly active in patients with FLT3-ITD mutated acute myeloid leukemia (AML)." @default.
• W3172808526 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e19019" @default.
• W3172808526 hasPublicationYear "2021" @default.
• W3172808526 type Work @default.
• W3172808526 sameAs 3172808526 @default.
• W3172808526 citedByCount "4" @default.
• W3172808526 countsByYear W31728085262021 @default.
• W3172808526 countsByYear W31728085262022 @default.
• W3172808526 countsByYear W31728085262023 @default.
• W3172808526 crossrefType "journal-article" @default.
• W3172808526 hasAuthorship W3172808526A5000750846 @default.
• W3172808526 hasAuthorship W3172808526A5009316700 @default.
• W3172808526 hasAuthorship W3172808526A5009423275 @default.
• W3172808526 hasAuthorship W3172808526A5010786159 @default.
• W3172808526 hasAuthorship W3172808526A5020340537 @default.
• W3172808526 hasAuthorship W3172808526A5020626623 @default.
• W3172808526 hasAuthorship W3172808526A5022647201 @default.
• W3172808526 hasAuthorship W3172808526A5028081179 @default.
• W3172808526 hasAuthorship W3172808526A5050041791 @default.
• W3172808526 hasAuthorship W3172808526A5055045706 @default.
• W3172808526 hasAuthorship W3172808526A5060758278 @default.
• W3172808526 hasAuthorship W3172808526A5061026876 @default.
• W3172808526 hasAuthorship W3172808526A5070065917 @default.
• W3172808526 hasAuthorship W3172808526A5079262854 @default.
• W3172808526 hasAuthorship W3172808526A5088280758 @default.
• W3172808526 hasAuthorship W3172808526A5088307376 @default.
• W3172808526 hasAuthorship W3172808526A5090435894 @default.
• W3172808526 hasAuthorship W3172808526A5091492845 @default.
• W3172808526 hasConcept C104317684 @default.
• W3172808526 hasConcept C126322002 @default.
• W3172808526 hasConcept C143998085 @default.
• W3172808526 hasConcept C150194340 @default.
• W3172808526 hasConcept C185592680 @default.
• W3172808526 hasConcept C190727270 @default.
• W3172808526 hasConcept C2776481607 @default.
• W3172808526 hasConcept C2776611710 @default.
• W3172808526 hasConcept C2776694085 @default.
• W3172808526 hasConcept C2777938653 @default.
• W3172808526 hasConcept C2778461978 @default.
• W3172808526 hasConcept C2778729363 @default.
• W3172808526 hasConcept C2779282312 @default.
• W3172808526 hasConcept C2779675984 @default.
• W3172808526 hasConcept C2780007613 @default.
• W3172808526 hasConcept C2780235182 @default.
• W3172808526 hasConcept C55493867 @default.
• W3172808526 hasConcept C71924100 @default.
• W3172808526 hasConceptScore W3172808526C104317684 @default.
• W3172808526 hasConceptScore W3172808526C126322002 @default.
• W3172808526 hasConceptScore W3172808526C143998085 @default.
• W3172808526 hasConceptScore W3172808526C150194340 @default.
• W3172808526 hasConceptScore W3172808526C185592680 @default.
• W3172808526 hasConceptScore W3172808526C190727270 @default.
• W3172808526 hasConceptScore W3172808526C2776481607 @default.
• W3172808526 hasConceptScore W3172808526C2776611710 @default.
• W3172808526 hasConceptScore W3172808526C2776694085 @default.
• W3172808526 hasConceptScore W3172808526C2777938653 @default.
• W3172808526 hasConceptScore W3172808526C2778461978 @default.
• W3172808526 hasConceptScore W3172808526C2778729363 @default.
• W3172808526 hasConceptScore W3172808526C2779282312 @default.
• W3172808526 hasConceptScore W3172808526C2779675984 @default.
• W3172808526 hasConceptScore W3172808526C2780007613 @default.
• W3172808526 hasConceptScore W3172808526C2780235182 @default.
• W3172808526 hasConceptScore W3172808526C55493867 @default.
• W3172808526 hasConceptScore W3172808526C71924100 @default.
• W3172808526 hasFunder F4320321625 @default.
• W3172808526 hasIssue "15_suppl" @default.
• W3172808526 hasLocation W31728085261 @default.
• W3172808526 hasOpenAccess W3172808526 @default.
• W3172808526 hasPrimaryLocation W31728085261 @default.
• W3172808526 hasRelatedWork W2889423049 @default.
• W3172808526 hasRelatedWork W2889428910 @default.
• W3172808526 hasRelatedWork W2936131736 @default.
• W3172808526 hasRelatedWork W3172808526 @default.
• W3172808526 hasRelatedWork W4206345074 @default.
• W3172808526 hasRelatedWork W4212990141 @default.
• W3172808526 hasRelatedWork W4220981828 @default.

• next